Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.43 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158733 | 0.83 | GPR35 (0.47) | GPR35MAPK1HPGDALDH1A1TP53 | |
| SCHEMBL57882 | 0.80 | TSHR (0.40) | GPR35MAPK1ALDH1A1TSHRALOX15 | |
| SCHEMBL15121292 | 0.79 | MAPK1 (0.33) | GPR35MAPK1HPGDALDH1A1TP53 | |
| SCHEMBL6800906 | 0.78 | TDP1 (0.38) | GPR35MAPK1ALDH1A1TP53TSHR | |
| SCHEMBL58127 | 0.77 | HSD17B10 (0.54) | ALDH1A1TSHRSMN1; SMN2L3MBTL1HSD17B10 | |
| SCHEMBL1028967 | 0.77 | TDP1 (0.50) | GPR35MAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL710076 | 0.75 | ALDH1A1 (0.47) | GPR35MAPK1HPGDALDH1A1TP53 | |
| SCHEMBL247495 | 0.75 | PARP1 (0.41) | GPR35MAPK1HPGDALDH1A1TSHR | |
| SCHEMBL19859 | 0.75 | VCAM1 (0.46) | GPR35MAPK1HPGDALDH1A1TSHR | |
| SCHEMBL2783828 | 0.75 | TDP1 (0.48) | GPR35MAPK1ALDH1A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303561-A1 | PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | claimed |
| CN-116162379-A | Degradable protective coating and preparation method thereof | 无锡市造漆厂有限公司 | 2023-05-26 | — | — | CN | claimed |
| EP-4180429-A1 | PYRIMIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2023-05-17 | — | — | EP | claimed |
| CN-115974844-A | 3,4,5-trimethoxyphenyl derivative and application thereof | 广东省科学院动物研究所 | 2023-04-18 | — | — | CN | claimed |
| CN-114081890-A | Application of pyrimidone derivatives in resisting mycobacterium tuberculosis infection | 中国医学科学院医药生物技术研究所 | 2022-02-25 | — | — | CN | claimed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| CN-111925368-B | Pyrimidone derivatives, preparation method thereof and application thereof in resisting mycobacterium tuberculosis infection | 中国医学科学院医药生物技术研究所 | 2021-11-05 | — | — | CN | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | claimed |
| CN-111925368-A | Pyrimidone derivatives, preparation method thereof and application thereof in resisting mycobacterium tuberculosis infection | 中国医学科学院医药生物技术研究所 | 2020-11-13 | — | — | CN | claimed |
| WO-2005113582-A1 | SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | claimed |
| CN-1216851-C | Process for producing bis (4-hydroxy-3-nitrophenyl) compound | NIPPON KAYAKU KK (JP) | 2005-08-31 | — | — | CN | claimed |
| CN-1426390-A | Process for producing bis (4-hydroxy-3-nitrophenyl) compound | NIPPON KAYAKU KK (JP) | 2003-06-25 | — | — | CN | claimed |
| US-6376548-B1 | FUNGICIDES; HERBICIDES; INSECTICIDES | ROHM AND HAAS COMPANY | 2002-04-23 | — | — | US | claimed |
| EP-0960084-A1 | NOVEL SOLID-PHASE SYNTHESIS TECHNIQUES FOR PREPARING MULTIPLE ANALOGOUS COMPOUNDS | AXYS PHARMACEUTICALS, INC. (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998033751-A1 | NOVEL SOLID-PHASE SYNTHESIS TECHNIQUES FOR PREPARING MULTIPLE ANALOGOUS COMPOUNDS | AXYS PHARMACEUTICALS, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0113572-B1 | PYRIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-02-03 | — | — | EP | claimed |
| US-4547506-A | 2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-10-15 | — | — | US | claimed |
| EP-0113572-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-18 | — | — | EP | claimed |
| US-4085261-A | CHELATING AGENT WITH A STYRENE POLYMER BACKBONE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303561-A1 | PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION | DHPS, DHFR, QDPR | GPR35 2796/4885MAPK1 954/4885HPGD 192/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | GPR35 1875/4885MAPK1 3817/4885HPGD 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.